Cryo-EM reveals how omecamtiv mecarbil readies myosin for phosphate release

Omecamtiv mecarbil (OM) was considered to be a cardiac muscle activator in clinical trials for alleviation of systolic heart failure. Yet, it was later shown to be a potent inhibitor of myosin motor activity. Its binding to myosin prevents the force-generating lever swing but also accelerates the release of inorganic phosphate (P i ), such that in muscle OM enhances overall force production by cooperatively increasing the number of actomyosin cross-bridges. The structural basis by which it accelerates P i release remains poorly understood. Here, using cryogenic electron microscopy, we determined the structure of the human β-cardiac myosin motor domain in the presence of MgATP and OM to 3.2 Å global resolution. The structure adopts a primed state with well resolved OM density within its established binding pocket, and density within the active site consistent with a post-hydrolysis MgADP·P i state. OM stabilizes interactions bridging the converter and N-terminal subdomains of the myosin motor, inducing a 11° lever rotation and altering relay-helix conformation relative to the drug-free motor to prevent the force-generating lever swing. Comparison of this structure with that of bovine cardiac myosin with OM and MgADP·vanadate bound, determined by crystallography, revealed subtle but meaningful differences. OM remodels the nucleotide-binding site, shifting the P i density ∼2 Å towards its proposed exit pathway. This altered P i coordination provides a plausible structural rationale for a mechanism by which OM accelerates the weak-to-strong actomyosin-binding transition, key to its therapeutic function. By stabilizing a conformation in which P i is not coordinated to MgADP, P i is likely freely released upon opening of its exit pathway. This structural observation is also consistent with previous kinetic studies that showed that OM shifts the equilibrium constant for ATP hydrolysis towards the post-hydrolysis state. This mechanistic understanding will be beneficial to the development of more effective myosin-targeting therapeutics.

Authors

Institutions

Publication Details

Journal
Acta Crystallographica Section D Structural Biology
Published
2026-11-19
DOI
https://doi.org/10.1107/s2059798326011836
Primary Topic
Cardiomyopathy and Myosin Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cryo-EM reveals how omecamtiv mecarbil readies myosin for phosphate release

Donald A. Winkelmann, Charlotte A. Scarff, Sean N. McMillan, Stephen P. Muench
Acta Crystallographica Section D Structural Biology
Cardiomyopathy and Myosin Studies
article

Cryo-EM reveals how omecamtiv mecarbil readies myosin for phosphate release

Donald A. Winkelmann, Charlotte A. Scarff, Sean N. McMillan, Stephen P. Muench
article en

Abstract

Omecamtiv mecarbil (OM) was considered to be a cardiac muscle activator in clinical trials for alleviation of systolic heart failure. Yet, it was later shown to be a potent inhibitor of myosin motor activity. Its binding to myosin prevents the force-generating lever swing but also accelerates the release of inorganic phosphate (P i ), such that in muscle OM enhances overall force production by cooperatively increasing the number of actomyosin cross-bridges. The structural basis by which it accelerates P i release remains poorly understood. Here, using cryogenic electron microscopy, we determined the structure of the human β-cardiac myosin motor domain in the presence of MgATP and OM to 3.2 Å global resolution. The structure adopts a primed state with well resolved OM density within its established binding pocket, and density within the active site consistent with a post-hydrolysis MgADP·P i state. OM stabilizes interactions bridging the converter and N-terminal subdomains of the myosin motor, inducing a 11° lever rotation and altering relay-helix conformation relative to the drug-free motor to prevent the force-generating lever swing. Comparison of this structure with that of bovine cardiac myosin with OM and MgADP·vanadate bound, determined by crystallography, revealed subtle but meaningful differences. OM remodels the nucleotide-binding site, shifting the P i density ∼2 Å towards its proposed exit pathway. This altered P i coordination provides a plausible structural rationale for a mechanism by which OM accelerates the weak-to-strong actomyosin-binding transition, key to its therapeutic function. By stabilizing a conformation in which P i is not coordinated to MgADP, P i is likely freely released upon opening of its exit pathway. This structural observation is also consistent with previous kinetic studies that showed that OM shifts the equilibrium constant for ATP hydrolysis towards the post-hydrolysis state. This mechanistic understanding will be beneficial to the development of more effective myosin-targeting therapeutics.

Acta Crystallographica Section D Structural BiologyVol. 82(12)
Rutgers, The State University of New Jersey (US), University of Leeds (GB)
Cardiomyopathy and Myosin Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon